676 related articles for article (PubMed ID: 26343027)
1. The Budget Impact of Biosimilar Infliximab (Remsima®) for the Treatment of Autoimmune Diseases in Five European Countries.
Jha A; Upton A; Dunlop WC; Akehurst R
Adv Ther; 2015 Aug; 32(8):742-56. PubMed ID: 26343027
[TBL] [Abstract][Full Text] [Related]
2. Budget impact analysis of biosimilar infliximab (CT-P13) for the treatment of rheumatoid arthritis in six Central and Eastern European countries.
Brodszky V; Baji P; Balogh O; Péntek M
Eur J Health Econ; 2014 May; 15 Suppl 1(Suppl 1):S65-71. PubMed ID: 24832837
[TBL] [Abstract][Full Text] [Related]
3. Efficacy, immunogenicity and cost analysis of a systematic switch from originator infliximab to biosimilar CT-P13 of all patients with inflammatory arthritis from a single center.
Valido A; Silva-Dinis J; Saavedra MJ; Iria I; Gonçalves J; Lopes JP; Fonseca JE
Acta Reumatol Port; 2019; 44(4):303-311. PubMed ID: 31754088
[TBL] [Abstract][Full Text] [Related]
4. The nocebo effect challenges the non-medical infliximab switch in practice.
Boone NW; Liu L; Romberg-Camps MJ; Duijsens L; Houwen C; van der Kuy PHM; Janknegt R; Peeters R; Landewé RBM; Winkens B; van Bodegraven AA
Eur J Clin Pharmacol; 2018 May; 74(5):655-661. PubMed ID: 29368188
[TBL] [Abstract][Full Text] [Related]
5. Cost of biologics per treated patient across immune-mediated inflammatory disease indications in a pharmacy benefit management setting: a retrospective cohort study.
Wu N; Lee YC; Shah N; Harrison DJ
Clin Ther; 2014 Aug; 36(8):1231-41, 1241.e1-3. PubMed ID: 25062652
[TBL] [Abstract][Full Text] [Related]
6. Infliximab Biosimilar (CT-P13; Infliximab-dyyb): A Review in Autoimmune Inflammatory Diseases.
Blair HA; Deeks ED
BioDrugs; 2016 Oct; 30(5):469-480. PubMed ID: 27650650
[TBL] [Abstract][Full Text] [Related]
7. Experience with Biosimilar Infliximab (Remsima®) in Norway.
Jahnsen J; Kaasen Jørgensen K
Dig Dis; 2017; 35(1-2):83-90. PubMed ID: 28147374
[TBL] [Abstract][Full Text] [Related]
8. Impact of a Patient Support Program on Patient Adherence to Adalimumab and Direct Medical Costs in Crohn's Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Psoriatic Arthritis, and Ankylosing Spondylitis.
Rubin DT; Mittal M; Davis M; Johnson S; Chao J; Skup M
J Manag Care Spec Pharm; 2017 Aug; 23(8):859-867. PubMed ID: 28737994
[TBL] [Abstract][Full Text] [Related]
9. Efficacious transition from reference infliximab to biosimilar infliximab in clinical practice.
Layegh Z; Ruwaard J; Hebing RCF; L' Ami MJ; van der Weele W; Nurmohamed MT; Krieckaert C; Wolbink G
Int J Rheum Dis; 2019 May; 22(5):869-873. PubMed ID: 30767391
[TBL] [Abstract][Full Text] [Related]
10. The Rituximab Biosimilar CT-P10 in Rheumatology and Cancer: A Budget Impact Analysis in 28 European Countries.
Gulácsi L; Brodszky V; Baji P; Rencz F; Péntek M
Adv Ther; 2017 May; 34(5):1128-1144. PubMed ID: 28397080
[TBL] [Abstract][Full Text] [Related]
11. Biosimilar monoclonal antibodies: the scientific basis for extrapolation.
Schellekens H; Lietzan E; Faccin F; Venema J
Expert Opin Biol Ther; 2015; 15(11):1633-46. PubMed ID: 26365396
[TBL] [Abstract][Full Text] [Related]
12. Analysis of clinical trials of biosimilar infliximab (CT-P13) and comparison against historical clinical studies with the infliximab reference medicinal product.
Yoo DH; Oh C; Hong S; Park W
Expert Rev Clin Immunol; 2015; 11 Suppl 1():S15-24. PubMed ID: 26395833
[TBL] [Abstract][Full Text] [Related]
13. Adoption of Biosimilar Infliximab for Rheumatoid Arthritis, Ankylosing Spondylitis, and Inflammatory Bowel Diseases in the EU5: A Budget Impact Analysis Using a Delphi Panel.
Kanters TA; Stevanovic J; Huys I; Vulto AG; Simoens S
Front Pharmacol; 2017; 8():322. PubMed ID: 28620302
[No Abstract] [Full Text] [Related]
14. Biosimilars for the management of rheumatoid arthritis: economic considerations.
Gulácsi L; Brodszky V; Baji P; Kim H; Kim SY; Cho YY; Péntek M
Expert Rev Clin Immunol; 2015; 11 Suppl 1():S43-52. PubMed ID: 26395836
[TBL] [Abstract][Full Text] [Related]
15. Impact of Infliximab and Etanercept Biosimilars on Biological Disease-Modifying Antirheumatic Drugs Utilisation and NHS Budget in the UK.
Aladul MI; Fitzpatrick RW; Chapman SR
BioDrugs; 2017 Dec; 31(6):533-544. PubMed ID: 29127626
[TBL] [Abstract][Full Text] [Related]
16. Estimation of cost savings between 2011 and 2014 attributed to infliximab biosimilar in the South Korean healthcare market: real-world evidence using a nationwide database.
Kim J; Ha D; Song I; Park H; Lee SW; Lee EK; Shin JY
Int J Rheum Dis; 2018 Jun; 21(6):1227-1236. PubMed ID: 29667324
[TBL] [Abstract][Full Text] [Related]
17. Will savings from biosimilars offset increased costs related to dose escalation? A comparison of infliximab and golimumab for rheumatoid arthritis.
Curtis JR; Xie F; Kay J; Kallich JD
Arthritis Res Ther; 2019 Dec; 21(1):285. PubMed ID: 31831064
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of persistence, retention "rate" and prescription pattern of original infliximab and infliximab CT-P13 in biologic-naïve patients with ulcerative colitis.
Valcuende-Rosique A; Borrás-Blasco J; Martínez-Badal S; Cortes X; Aparicio-Rubio C; Casterá-Melchor E
Farm Hosp; 2022 Jun; 46(5):296-300. PubMed ID: 36183230
[TBL] [Abstract][Full Text] [Related]
19. Budget Impact Analysis of Biosimilar Trastuzumab for the Treatment of Breast Cancer in Croatia.
Cesarec A; Likić R
Appl Health Econ Health Policy; 2017 Apr; 15(2):277-286. PubMed ID: 27730538
[TBL] [Abstract][Full Text] [Related]
20. Budget Impact of Switching to Biosimilar Trastuzumab (CT-P6) for the Treatment of Breast Cancer and Gastric Cancer in 28 European Countries.
Lee SM; Jung JH; Suh D; Jung YS; Yoo SL; Kim DW; Kim JA; Suh DC
BioDrugs; 2019 Aug; 33(4):423-436. PubMed ID: 31201616
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]